A. Kadiri et al., COMPARISON OF NOVOPEN 3 AND SYRINGES VIALS IN THE ACCEPTANCE OF INSULIN THERAPY IN NIDDM PATIENTS WITH SECONDARY FAILURE TO ORAL HYPOGLYCEMIC AGENTS/, Diabetes research and clinical practice, 41(1), 1998, pp. 15-23
This open, randomised, cross-over study compared the acceptance and sa
fety of NovoPen 3 with that of conventional syringes and vials when in
itiating insulin treatment in 96 NIDDM patients with secondary failure
to oral hypoglycaemic agents. These patients had not previously been
treated with insulin. All patients used each insulin administration sy
stem for 12 weeks. Group A started therapy using NovoPen 3 and crossed
over to syringe/vial administration; Group B started with syringe/via
l administration followed by NovoPen 3. In total, 78 patients complete
d the study. Most patients in Group A initially found the insulin inje
ctions very easy or easy and many of those who found injections easy a
t first found them very easy by the end of week 12. During the first p
eriod, patients in Group B found insulin administration more difficult
than those in Group A. Injection pain was significantly lower with No
voPen 3 than with syringes and vials (P = 0.0018). Patients in Group B
reported a significantly lower level of injection pain after the swit
ch to using NovoPen 3 (P = 0.0003). Acceptance of insulin injections w
as significantly higher by patients using NovoPen 3 than by those usin
g syringes and vials (P = 0.0059). Setting and drawing up the dose of
insulin was also easier for patients using NovoPen 3 (P = 0.0490). At
the end of the study, most patients (89.5%, (68/76 replies)) said that
they preferred NovoPen 3 to syringes and vials. Glycaemic control imp
roved compared with baseline after starting insulin therapy, with no d
ifferences between Groups A and B, or between the two injection system
s. The number of reported hypoglycaemic episodes was very low and was
not significantly different between Groups A and B, or between the two
administration systems. No treatment-related adverse events were repo
rted. We conclude that use of NovoPen 3 provides better acceptance of
insulin injections than use of conventional syringes and vials during
initiation of insulin therapy in NIDDM patients with secondary failure
to treatment with oral hypoglycaemic agents. (C) 1998 Published by El
sevier Science Ireland Ltd. All rights reserved.